Stacie Lindsey

Stacie Lindsey

Auto-generated profile, based on publicly available information

Stacie Lindsey

Colangiocarcinoma Foundation

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
LPLeontios Pappas
Leontios Pappas
IBIslam Baiev
Islam Baiev
SRStephanie Reyes
Stephanie Reyes
ABAndrea Grace Bocobo
Andrea Grace Bocobo
AJApurva Jain
Apurva Jain
LGLipika Goyal
Lipika Goyal
PURPOSE: Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes for this population. However, in cholangiocarcinoma (CCA), a paucity of data exist on the AYA population. To our knowledge, we present the largest study to date on AYA disease biology, treatment patterns, and survival outcomes in CCA. METHODS: A multi-institutional cohort of patients with CCA diagnosed with intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma (ECC) was used for analysis. Retrospective chart review was conducted on patients who were 50 years old and younger (young; n = 124) and older than 50 years (older; n = 723). RESULTS: Among 1,039 patients screened, 847 patients met eligibility (72% ICC, 28% ECC). Young patients had a larger median tumor size at resection compared with older patients (4.2 v 3.6 cm; P = .048), more commonly had N1 disease (65% v 43%; P = .040), and were more likely to receive adjuvant therapy (odds ratio, 4.0; 95% CI, 1.64 to 9.74). Tumors of young patients were more likely to harbor an FGFR2 fusion, BRAF mutation, or ATM mutation ( P < .05 for each). Young patients were more likely to receive palliative systemic therapy (96% v 69%; P < .001), targeted therapy (23% v 8%; P < .001), and treatment on a clinical trial (31% v 19%; P = .004). Among patients who presented with advanced disease, young patients had a higher median overall survival compared with their older counterparts (17.7 v 13.5 months; 95% CI, 12.6 to 22.6 v 11.4 to 14.8; P = .049). CONCLUSION: Young patients with CCA had more advanced disease at resection, more commonly received both adjuvant and palliative therapies, and demonstrated improved survival compared with older patients. Given the low clinical trial enrollment and poor outcomes among some AYA cancer populations, data to the contrary in CCA are highly encouraging.

27 July 2022 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
JKJessica M. Keilson
Jessica M. Keilson
SLStacie Lindsey
Stacie Lindsey
MBMelinda Bachini
Melinda Bachini
CMCaroline R. Medin
Caroline R. Medin
ABAlexandra Berk
Alexandra Berk
SMShishir K. Maithel
Shishir K. Maithel

23 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
TZTingting Zhang
Tingting Zhang
JVJuan Valle
Juan Valle
APAshokkumar A. Patel
Ashokkumar A. Patel
SLStacie Lindsey
Stacie Lindsey
ASAki Smith
Aki Smith
THTony Kin Wai Hung
Tony Kin Wai Hung
Historically, data from US death certificates, available through the CDC’s WONDER database, have been used to highlight health disparities. The 5 year (2018-2022) underlying-cause-of-death data were analyzed for different race/ethnicity groups. Gastrointestinal (GI) cancers of the colon/rectum, pancreas, liver/bile duct, and stomach contributed to more than a quarter of cancer deaths in the US, calling for focused advocacy. Known disparities for Black non-Hispanic Americans were verified in cancers of the colon/rectum, and pancreas. However, mortality data for “More than one race” non-Hispanic group or non-White Hispanic group appeared unreliable, suggesting that under-reporting is also a sign of health disparity. Age-specific death rates (ASDRs) were calculated to view health disparities in various age groups. Cancers of the colon/rectum, liver, and stomach cause significant mortality in the under-50 population. And minority groups are more likely to die from cancers in the liver or the stomach compared to the White non-Hispanics. Liver cancer crude death rate was lower than expect in Asian Non-Hipanics when compared with the high mortalities of IARC’s GLOBOCAN estimates for Asian countries. Census data were then used to calculate Asian sub-groups’ ASDRs. Significantly higher risks were seen in gastric cancer for Korean Americans and liver cancer for Vietnamese Americans. The Asian Indian group had the lowest death rates across several GI cancers, even in gallbladder cancer. Some immigrants go back to their birth countries at end of life and these deaths are not reflected in WONDER because consulate reports of American citizens’ deaths abroad do not include race/ethnicity data. SIGNIFICANCE Gastrointestinal cancers should be advocacy focuses to promote cancer equity. Under-reporting of deaths for minority groups is a sign of health disparity. ASDRs (Age Specific Death Rates) provide bases for tailored screening and prevention. Exclusion of American citizen’s deaths abroad in U.S. public health datasets may mask care access issues faced by immigrant cancer patients who may die overseas. Updating how these deaths are reported will help address this issue.